Background/Aims A clinical unmet need persists for medications capable of modulating the progression of primary sclerosing cholangitis (PSC). This study aimed to assess the clinical feasibility of HK-660S (beta-lapachone) in PSC.
Methods In this multicenter, randomized, double-blind, placebo-controlled, parallel-group phase 2 trial, participants were assigned in a 2:1 ratio to receive either 100 mg of HK-660S or a placebo twice daily for 12 weeks. The primary outcomes were the reduction in serum alkaline phosphatase (ALP) levels and the percentage of participants showing improvements in PSC severity, as determined by magnetic resonance cholangiopancreatography with the Anali score. Secondary endpoints included changes in liver stiffness and adverse events.
Results The analysis included 21 patients, 15 receiving HK-660S, and six receiving a placebo. Improvements in the Anali score were observed in 13.3% of the HK-660S group, with no improvements in the placebo group. HK-660S treatment resulted in a 15.2% reduction in mean ALP levels, compared to a 6.6% reduction in the placebo group. A stratified ad-hoc analysis based on baseline ALP levels showed a statistically significant response in the HK-660S group among those with ALP levels greater than twice the upper limit of normal, with a 50% responder rate (p=0.05). Additionally, 26.7% of the HK-660S group showed improvements in the enhanced liver fibrosis score, with no improvements in the placebo group. HK-660S was generally well tolerated.
Conclusions HK-660S is well tolerated among patients with PSC and may improve bile duct strictures, decrease serum ALP levels, and reduce liver fibrosis (cris.nih.go.kr, Number KCT0006590).
Citations
Citations to this article as recorded by
Pruritus in Chronic Cholestatic Liver Diseases, Especially in Primary Biliary Cholangitis: A Narrative Review Tatsuo Kanda, Reina Sasaki-Tanaka, Naruhiro Kimura, Hiroyuki Abe, Tomoaki Yoshida, Kazunao Hayashi, Akira Sakamaki, Takeshi Yokoo, Hiroteru Kamimura, Atsunori Tsuchiya, Kenya Kamimura, Shuji Terai International Journal of Molecular Sciences.2025; 26(5): 1883. CrossRef
Future Treatment Options for Managing Primary Sclerosing Cholangitis and Cholestatic Pruritus Taranika Sarkar Das, Raj Vuppalanchi Clinics in Liver Disease.2025; 29(4): 781. CrossRef
Kyung-Ah Kim, M.D.1, Sook-Hyang Jeong, M.D.2, Jung Il Lee, M.D.3, Jong Eun Yeon, M.D.4, Heon Ju Lee, M.D.5, So Young Kwon, M.D.6, U Im Chang, M.D.7, Hyun Ju Min, M.D.8
Korean J Hepatol 2010;16(2):139-146. Published online June 25, 2010
Background/Aims This study investigated the clinical features and prognosis of primary biliary cirrhosis (PBC) in Korea. Methods: Clinical data of patients diagnosed as PBC between 1997 and 2008 at eight referral hospitals were analyzed retrospectively. PBC was diagnosed based on liver function tests, presence of serum antimitochondrial antibody (AMA), and histopathological findings. Results: In total, 251 patients (218 females, 33 males, mean age 54 years) were enrolled, and the mean follow-up duration was 33.5 months. At the diagnosis, 61% of the patients were asymptomatic, 12% had decompensated liver cirrhosis, and 98% were positive for AMA. The serum alkaline phosphate (AlP) level was 2.6 times the upper limit of normal, aspartate aminotransferase was 105 U/l, and bilirubin was 2.0 mg/dl. The mean Mayo risk score was 5.5, and the Child-Pugh class was A, B, and C in 79%, 19%, and 2% of the patients, respectively. Ursodeoxycholic acid (UDCA) was used for treatment in 88% of the patients, among which 70% exhibited biochemical responses defined as normalization or a >40% decrease in AlP at 6 months. Eight deaths occurred during the follow-up, the causes were variceal bleeding, hepatic failure, and sepsis. The overall 5-year survival rate was 95%. The poor prognostic factors were being older than 60 years, high bilirubin, low albumin, ascites, high Mayo risk score, Child-Pugh class C, and initial presence of hepatic decompensation. Conclusions: Most patients diagnosed as PBC were asymptomatic, and these patients had a favorable short-term prognosis. The prognosis of PBC was dependent on the initial severity of liver disease.
Citations
Citations to this article as recorded by
Clinical Characteristics and Prognosis of Concomitant Primary Biliary Cholangitis and Autoimmune Diseases: A Retrospective Study Yuwei Liu, Kai Han, Chen Liu, Fangfang Duan, Jun Cheng, Song Yang, Alessandro Granito Canadian Journal of Gastroenterology and Hepatology.2021;[Epub] CrossRef
Current epidemiology and clinical characteristics of autoimmune liver diseases in South Korea Sook-Hyang Jeong Clinical and Molecular Hepatology.2018; 24(1): 10. CrossRef
Clinical Features and Response to UDCA Treatment of Primary Biliary Cirrhosis Joo Young Kim, Tae Hun Kim, Kwon Yoo, Ye Ji Han, Jeong Eun Choi, Ji Yoon Kim, Min-Sun Cho The Ewha Medical Journal.2015; 38(3): 106. CrossRef
Primary biliary cirrhosis: Clinical and laboratory criteria for its diagnosis Vasiliy Ivanovich Reshetnyak World Journal of Gastroenterology.2015; 21(25): 7683. CrossRef
The Clinical Significance of Simplified Scoring Criteria as a Diagnostic Tool for Overlap Syndrome in Korea Min Suk Kim, Young Seok Kim, Sang Gyune Kim, Jin Myung Byun, La Young Yoon, Dong Hoon Han, Jong Joo Moon, Jae-Hyung Nam, Tae-Jin Kim, Sae Hwan Lee, Seung Won Jung, Hong Soo Kim, Boo sung Kim, Hee Kyung Kim Korean Journal of Medicine.2013; 84(2): 211. CrossRef
Management of Primary Biliary Cirrhosis Kyung-Ah Kim Korean Journal of Medicine.2012; 82(1): 32. CrossRef
Beneficial effects of candesartan, an angiotensin‐blocking agent, on compensated alcoholic liver fibrosis ‐ A randomized open‐label controlled study Moon Young Kim, Mee Yon Cho, Soon Koo Baik, Phil Ho Jeong, Ki Tae Suk, Yoon Ok Jang, Chang Jin Yea, Jae Woo Kim, Hyun Soo Kim, Sang Ok Kwon, Byung Su Yoo, Jang Young Kim, Min Seob Eom, Seung Hwan Cha, Sei Jin Chang Liver International.2012; 32(6): 977. CrossRef
Prognostic indicators in primary biliary cirrhosis: significance of revised IAHG (International Autoimmune Hepatitis Group) score Ho Eun Jung, Jae Young Jang, Soung Won Jeong, Jin Nyoung Kim, Hee Yoon Jang, Yun Ju Cho, Sung Ae Woo, Sae Hwan Lee, Sang Gyune Kim, Sang-Woo Cha, Young Seok Kim, Young Deok Cho, Hong Soo Kim, Boo Sung Kim Clinical and Molecular Hepatology.2012; 18(4): 375. CrossRef
The diagnosis and treatment of primary biliary cirrhosis Kyung-Ah Kim, Sook-Hyang Jeong The Korean Journal of Hepatology.2011; 17(3): 173. CrossRef
Prognosis of Korean patients with primary biliary cirrhosis Byung-Cheol Song The Korean Journal of Hepatology.2010; 16(2): 109. CrossRef
First
Prev
